Overview

Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo in Generalized Anxiety Disorder

Status:
Completed
Trial end date:
2007-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to demonstrate that quetiapine SR (SEROQUEL®) is efficacious and safe in the acute treatment of patients with Generalized Anxiety Disorder. PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.
Phase:
Phase 3
Details
Lead Sponsor:
AstraZeneca
Treatments:
Quetiapine Fumarate